Imidazole-based Ru(III) complexes: synthesis, characterisation and anticancer activity

Area of Science:

• Inorganic Chemistry
• Medicinal Chemistry
• Cancer Research

Background:

• Ruthenium(III) complexes are investigated for anticancer properties.
• NAMI-A is a clinically evaluated Ru(III) complex with known biological activity.
• Modulating ligand structures can alter the efficacy and selectivity of metal-based drugs.

Purpose of the Study:

• To synthesize and characterize novel imidazole-derived Ru(III) complexes.
• To evaluate the in vitro cytotoxicity and antimigratory effects of these complexes.
• To explore the structure-activity relationships and potential mechanisms of action.

Main Methods:

• Synthesis of five Ru(III) complexes (ImRu1-ImRu5) with varying imidazole substituents.
• Characterization using NMR, UV-Vis, elemental analysis, mass spectrometry, and X-ray diffraction.
• In vitro cytotoxicity assays against various cancer and non-cancer cell lines.
• Antimigratory assays and computational/fluorescence studies.

Main Results:

• All synthesized Ru(III) complexes exhibited low cytotoxicity and antimigratory activity comparable to NAMI-A.
• The ImRu3 complex, featuring an alkyne substituent, demonstrated selective cytotoxicity against A549, MeWo, and T24 cancer cells.
• ImRu3 also retained antimigratory activity against T24 cells.
• Functional modifications on the imidazole ligand influenced albumin-binding affinity.

Conclusions:

• Imidazole ligand modifications can significantly modulate the biological behavior of Ru(III) complexes.
• The ImRu3 complex shows promise as a selective anticancer agent.
• Enhanced albumin binding may contribute to the observed anticancer activity and improved transport.